Eloxx Prescription drugs to Report Fourth Quarter and Total Year 2020 Money Final results and Offer Enterprise Update on March 11, 2021

Organization administration to host a webcast and conference phone to present a small business update and overview financial success at 4:30 p.m. ET

WALTHAM, Mass., March 04, 2021 (Globe NEWSWIRE) — Eloxx Prescribed drugs, Inc. (NASDAQ: ELOX), a medical-phase biopharmaceutical enterprise dedicated to the discovery and improvement of novel therapeutics to deal with cystic fibrosis and other illnesses caused by nonsense mutations limiting generation of practical proteins, these days announced that it will release its fourth quarter and total 12 months 2020 economic and operational success and host a conference connect with and live webcast on Thursday, March 11, 2021.

Meeting Get in touch with Details:
Day: Thursday, March 11, 2021
Time: 4:30 p.m. ET
Domestic Dial-in Variety: (866) 913-8546
International Dial-in Number: (210) 874-7715
Convention ID: 4772135
Stay Webcast: available from the Firm’s web site at www.eloxxpharma.com under Functions and Displays or with this website link: https://edge.media-server.com/mmc/p/m65hdyjn.

About Eloxx Prescribed drugs

Eloxx Pharmaceuticals, Inc. is a scientific-phase biopharmaceutical firm producing novel RNA-modulating drug candidates (developed to be eukaryotic ribosomal selective glycosides) that are formulated to deal with uncommon and ultra-exceptional premature halt codon diseases. Premature quit codons are level mutations that disrupt protein synthesis from messenger RNA. As a consequence, sufferers with premature halt codon conditions have lessened or removed protein creation from the mutation bearing allele accounting for some of the most critical phenotypes in these genetic health conditions. These untimely end codons have been identified in over 1,800 unusual and extremely-rare disorders. Read through-by means of therapeutic advancement is concentrated on extending mRNA fifty percent-everyday living and raising protein synthesis by enabling the cytoplasmic ribosome to go through by way of premature quit codons to produce full-duration proteins. Eloxx’s guide investigational item candidate, ELX-02, is a smaller molecule drug prospect built to restore manufacturing of full-duration practical proteins. ELX-02 is in the early levels of scientific enhancement focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been authorized by any global regulatory entire body. Eloxx’s preclinical prospect pool consists of a library of novel drug candidates built to be eukaryotic ribosomal selective glycosides identified centered on go through-by way of likely. Eloxx also has preclinical plans centered on kidney conditions like autosomal dominant polycystic kidney condition, as very well as unusual ocular genetic conditions. Eloxx is headquartered in Waltham, MA, with functions in Rehovot, Israel and Morristown, NJ. For extra details, make sure you pay a visit to www.eloxxpharma.com.

Ahead-Hunting Statements

This push release incorporates ahead-on the lookout statements, which are frequently statements that are not historic details. Ahead-on the lookout statements can be identified by the words and phrases “expects,” “anticipates,” “believes,” “intends,” “estimates,” “designs,” “will,” “outlook” and similar expressions. Forward-hunting statements are dependent on management’s current ideas, estimates, assumptions and projections, and discuss only as of the day they are designed. We undertake no obligation to update any forward-hunting statement in mild of new information or potential events, other than as in any other case required by law. Ahead-on the lookout statements contain inherent pitfalls and uncertainties, most of which are complicated to predict and are frequently past our manage. Actual results or results might vary materially from all those implied by the forward-on the lookout statements as a outcome of the influence of a variety of factors, together with: the advancement of the Company’s study-by means of technological know-how the acceptance of the Company’s patent apps the Company’s ability to correctly defend its mental home or obtain required licenses at a expense appropriate to the Organization, if at all the effective implementation of the Company’s study and development systems and collaborations the Company’s skill to attain relevant regulatory approvals for its existing and future merchandise candidates the acceptance by the current market of the Company’s products ought to they acquire regulatory acceptance the timing and success of the Company’s preliminary research, preclinical investigation, clinical trials, and relevant regulatory filings the skill of the Enterprise to consummate extra financings as required the impact of world-wide well being considerations, these as the COVID-19 international pandemic, on our capacity to go on our clinical and preclinical plans and in any other case run our business enterprise successfully as perfectly as all those reviewed in more depth in our Annual Report on Type 10-K and our other reviews filed with the Securities and Exchange Fee.

Barbara Ryan
[email protected]
(203) 274-2825

Supply: Eloxx Prescription drugs, Inc.